Survodutide For Lab Research

Buy Survodutide UK – >99% Purity | GCGR/GLP-1R Dual Agonist | Research Use Only

Survodutide (also known as BI 456906) is a synthetic 29-amino acid dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), and one of the most clinically advanced compounds in metabolic and obesity research today. Buy Survodutide in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in-vitro research use only.

What is Survodutide?

Survodutide (BI 456906) is a 29-amino acid synthetic peptide developed by Boehringer Ingelheim, derived from glucagon with the incorporation of potent GLP-1 receptor activity. It contains a C18 diacid chain that mediates albumin binding, extending its plasma half-life to support once-weekly dosing in research models.

What distinguishes Survodutide from other compounds in this class is its dual receptor engagement — simultaneously activating both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). This dual mechanism allows researchers to study two complementary and reinforcing pathways at once: GLP-1R agonism reduces appetite and food intake, while GCGR agonism increases energy expenditure and promotes fat metabolism in the liver. Together, this creates a more potent metabolic effect than GLP-1 receptor agonism alone.

Survodutide is currently in Phase 3 clinical trials (SYNCHRONIZE programme), making it one of the most clinically well-validated research peptides currently available from UK peptides suppliers.

How Does Survodutide Work?

Survodutide functions through balanced co-agonism of two key metabolic receptors:

GLP-1 Receptor (GLP-1R) Activation:

• Suppresses appetite and reduces caloric intake through central satiety signalling
• Slows gastric emptying, prolonging the sensation of fullness
• Promotes insulin secretion in a glucose-dependent manner
• Reduces post-meal glucose excursions

Glucagon Receptor (GCGR) Activation:

• Increases energy expenditure through hepatic and thermogenic pathways
• Promotes fatty acid oxidation and lipolysis in the liver
• Increases circulating FGF21 — a metabolic hormone linked to fat burning and insulin sensitivity
• Upregulates liver NNMT mRNA expression, a validated biomarker of GCGR engagement
• Adds a catabolic energy-expenditure component absent in GLP-1 mono-agonists such as semaglutide

The result is a compound that addresses both sides of the energy balance equation in research models — reducing intake via GLP-1R and increasing expenditure via GCGR — making it one of the most mechanistically complete metabolic research tools available.

What Does Survodutide Do in Research?

In pre-clinical and clinical research models, Survodutide has demonstrated a broad range of metabolically significant effects:

• Superior body weight reduction — Phase 2 data demonstrated mean bodyweight reductions approximately 5× greater than placebo at 4.8 mg weekly over 46 weeks, with over half of participants reaching ≥15% bodyweight reduction
• Outperforms semaglutide comparisons — Phase 2 Phase results for Survodutide (18.7% bodyweight reduction at 4.8 mg weekly) positioned it above approved GLP-1 mono-agonist benchmarks in research comparisons
• Pre-clinical obesity models — in diet-induced obese (DIO) mice, Survodutide achieved 25% bodyweight reduction from baseline over 28 days at 30 nmol/kg
• Glycaemic control — demonstrated significant HbA1c reduction in Phase 2 trials in people with type 2 diabetes, comparable to selective GLP-1R agonism, while also achieving clinically meaningful bodyweight loss
• Liver and MASLD models — GCGR agonism is specifically studied in metabolic-associated steatotic liver disease (MASLD) and MASH models, where glucagon receptor activation has demonstrated anti-steatotic properties
• Cardiovascular research — the ongoing SYNCHRONIZE-CVOT Phase 3 trial is investigating cardiovascular outcomes in adults with obesity and established cardiovascular disease or chronic kidney disease — a first for a dual GCGR/GLP-1R agonist in this scale of trial
• Energy expenditure pathway research — FGF21 and NNMT upregulation confirmed as validated in vivo biomarkers of GCGR engagement, offering researchers reliable pharmacodynamic readouts

What Do Studies Say About Survodutide?

Survodutide has one of the most robust published research profiles of any compound in its class:

• le Roux CW et al. (2024) — The Lancet Diabetes & Endocrinology, 12(3): 162–173 — Landmark Phase 2 randomised, double-blind, placebo-controlled trial across 43 centres in 12 countries. In adults with BMI ≥27 kg/m² without diabetes, Survodutide 4.8 mg once weekly produced mean bodyweight reductions approximately 5× greater than placebo over 46 weeks, with >50% of participants achieving ≥15% bodyweight reduction. DOI: 10.1016/S2213-8587(23)00356-X
• Thomas L et al. (2024) — Diabetes, Obesity and Metabolism, 26(6): 2368–2378 — Pharmacological profiling study confirming Survodutide’s balanced dual GCGR/GLP-1R pharmacology. Demonstrated 25% bodyweight reduction in DIO mice over 28 days, significant glucose tolerance improvement (54% AUC reduction vs vehicle), and confirmed FGF21 and NNMT mRNA as validated GCGR engagement biomarkers. DOI: 10.1111/dom.15551
• Klein T et al. (2024) — Diabetes Research and Clinical Practice, 207: 110779 — Mechanistic review confirming Survodutide’s derivation from glucagon with incorporated GLP-1 activity and albumin-binding C18 diacid for extended half-life. Reviewed Phase 2 HbA1c and bodyweight data in type 2 diabetes populations. DOI: 10.1016/j.diabres.2023.110779
• Zimmermann T et al. (2022) — Molecular Metabolism, 66: 101633 — Discovery and pre-clinical pharmacology paper for Survodutide (BI 456906), confirming robust anti-obesity efficacy in multiple pre-clinical models and establishing the pharmacological rationale for dual GCGR/GLP-1R agonism as a superior approach to GLP-1 monotherapy.
• Meta-analysis (2024) — Diabetology & Metabolic Syndrome — Systematic review and meta-analysis of 18 treatment arms (1,029 participants) confirmed significant reductions in bodyweight (WMD: −8.33 kg), BMI (WMD: −4.03 kg/m²), and waist circumference (WMD: −6.33 cm) following Survodutide versus control. Longer interventions (>16 weeks) and higher doses (>2 mg/week) associated with greater reductions. DOI: 10.1186/s13098-024-01501-x
• SYNCHRONIZE-CVOT (ongoing Phase 3) — JACC: Heart Failure — Global cardiovascular outcomes trial targeting 4,935 participants with obesity and established cardiovascular or chronic kidney disease. Primary endpoint: time to first MACE (5-point composite). First Phase 3 cardiovascular safety study of a dual GCGR/GLP-1R agonist at this scale. NCT06077864. DOI: 10.1016/j.jchf.2024.09.004Note: Phase 2 and Phase 3 clinical trial data relate to pharmaceutical development research. Survodutide is not approved for medical or therapeutic use. All supply from Peptides Lab UK is for in-vitro and laboratory research use only.

What is Survodutide Used For in Research?

Researchers purchasing Survodutide from UK peptides suppliers like Peptides Lab UK typically focus on:

• Dual GCGR/GLP-1R receptor binding, activation, and co-agonism studies
• Obesity and metabolic syndrome pre-clinical and in-vitro models
• Energy expenditure and fatty acid oxidation pathway research
• Type 2 diabetes and glycaemic control investigation
• Liver steatosis, MASLD, and MASH model studies
• Cardiovascular metabolic risk and cardiac energy metabolism research
• FGF21 and NNMT as pharmacodynamic biomarkers of GCGR engagement
• Comparative dual agonist research alongside tirzepatide, mazdutide, and pemvidutide
• Structure–activity relationship (SAR) studies within the incretin mimetic class
• Chronic kidney disease and cardiometabolic risk interaction studies

Survodutide vs Other Metabolic Research Peptides

Feature	Survodutide	Semaglutide	Tirzepatide
Receptor Targets	GCGR + GLP-1R	GLP-1R only	GIP + GLP-1R
Energy Expenditure Boost	Yes (via GCGR)	Limited	Limited
Appetite Suppression	Yes (via GLP-1R)	Yes	Yes
Liver/MASLD Research	Strong	Moderate	Moderate
Clinical Stage	Phase 3	Approved	Approved
Half-Life Extension	C18 diacid / albumin binding	Fatty acid chain	Fatty acid chain

Survodutide’s unique GCGR engagement makes it the preferred research tool when studying the hepatic and energy expenditure components of metabolic disease, which GLP-1 mono-agonists do not fully address.

Quality & Purity Assurance

Every batch of Survodutide from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Why Buy Survodutide from Peptides Lab UK?

When you buy Survodutide in the UK from Peptides Lab UK, you receive:

99% purity, HPLC and MS verified, third-party tested

• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer: All products supplied by Peptides Lab UK are intended strictly for in-vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. Survodutide (BI 456906) is an investigational compound currently in Phase 3 clinical trials and has not been approved by the MHRA, FDA, or any regulatory authority for human use. All research citations on this page relate to pre-clinical studies, clinical trial data published for scientific purposes, and peer-reviewed pharmacological research. They do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.